HK3, in turn, impairs TAM cross-presentation capacity by promoting TFEB nuclear translocation and excessive lysosomal activation and antigen degradation, thereby undermining anti-tumor immunity; targeting HK3 restores antigen presentation and synergizes with immune checkpoint blockade (91). This evidence concerns the gene HK3 and neoplasm.